Loading...
XASE
CATX
Market cap273mUSD
Aug 01, Last price  
3.68USD
1D
-4.17%
1Q
43.75%
Jan 2017
-36.55%
IPO
-73.71%
Name

IsoRay Inc

Chart & Performance

D1W1MN
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-60.57%
Rev. gr., 5y
-27.81%
Revenues
0k
-100.00%
1,994,3065,738,0337,158,6905,417,8155,286,0845,238,9735,071,0884,525,2334,219,1584,606,5394,769,2764,761,0005,923,0007,314,0009,680,00010,053,00010,795,0007,104,0001,434,0000
Net income
-79m
L+70.46%
-8,218,130-9,605,155-8,557,507-6,160,841-4,033,856-2,842,213-3,488,905-3,856,596-5,959,122-3,681,051-4,710,808-6,162,000-6,700,000-4,850,000-3,269,000-3,188,000-7,153,000-14,670,000-46,508,000-79,279,000
CFO
-18m
L-50.44%
-7,003,077-7,201,710-7,725,298-3,948,936-2,686,403-2,418,910-2,447,775-3,056,267-3,228,221-3,521,858-3,884,000-5,712,000-5,712,000-5,049,000-3,641,000-2,837,000-7,710,000-12,172,000-36,913,000-18,294,000

Profile

Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
URL
https://isoray.com/
IPO date
May 31, 2002
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122022‑062021‑062020‑062019‑062018‑062017‑062016‑06
Income
Revenues
1,434
-86.72%
7,104
-29.33%
Cost of revenue
68,251
42,375
22,166
Unusual Expense (Income)
NOPBT
(68,251)
(40,941)
(15,062)
NOPBT Margin
Operating Taxes
(2,097)
(2,651)
Tax Rate
NOPAT
(66,154)
(38,290)
(15,062)
Net income
(79,279)
70.46%
(46,508)
550.19%
(14,670)
360.16%
Dividends
Dividend yield
Proceeds from repurchase of equity
275,807
364
BB yield
-13,420.24%
-0.34%
Debt
Debt current
957
95
Long-term debt
3,813
3,282
Deferred revenue
Other long-term liabilities
28,280
Net debt
(222,146)
(5,994)
(43,907)
Cash flow
Cash from operating activities
(18,294)
(36,913)
(12,172)
CAPEX
(54,414)
(1,072)
(302)
Cash from investing activities
(218,931)
24,373
(57,678)
Cash from financing activities
289,385
785
56
FCF
(119,367)
(41,092)
(19,255)
Balance
Cash
226,916
9,238
43,757
Long term investments
133
150
Excess cash
226,916
9,299
43,552
Stockholders' equity
(231,700)
(152,158)
(105,790)
Invested Capital
553,033
229,888
161,205
ROIC
ROCE
EV
Common stock shares outstanding
644
26,764
142,103
Price
3.19
-20.65%
4.02
30.10%
2.47
-69.03%
Market cap
2,055
-98.09%
107,592
-75.48%
351,137
-57.62%
EV
(220,091)
101,598
307,230
EBITDA
(65,945)
(39,995)
(14,718)
EV/EBITDA
3.34
Interest
48
84
Interest/NOPBT